- Retraction: A Case of Rapid Progression of Hepatocellular Carcinoma after Radiofrequency Ablation
-
Lee K, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2198527
- J Liver Cancer.
- 2016 Mar;16(1):67-67.
- doi: 10.17998/jlc.2016.16.1.67
To preserve scientific integrity, Journal of Liver Cancer agreed with the authors that this paper be retracted. -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View
-
Izumi N
- KMID: 2198516
- J Liver Cancer.
- 2016 Mar;16(1):7-11.
- doi: 10.17998/jlc.2016.16.1.7
Transarterial chemoembolization (TACE) is recommended as the first line treatment option for the patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), however, treatment strategy and evaluation... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
-
Song DS, Bae SH
- KMID: 2198515
- J Liver Cancer.
- 2016 Mar;16(1):1-6.
- doi: 10.17998/jlc.2016.16.1.1
Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Subclassification of Hepatocellular Carcinoma with Barcelona Clinic Liver Cancer Intermediate Stage
-
Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK
- KMID: 2198518
- J Liver Cancer.
- 2016 Mar;16(1):17-22.
- doi: 10.17998/jlc.2016.16.1.17
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to sub-classify hepatocellular carcinoma with BCLC intermediate stage for better... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Complete Remission in Patient with Extrahepatic Metastasis after Curative Resection of Hepatocellular Carcinoma by Radiotherapy, Lung Resection and Systemic Chemotherapy
-
Kim YJ, Lee HW, Lee JH, Sung JS, Kim DY
- KMID: 2198526
- J Liver Cancer.
- 2016 Mar;16(1):63-66.
- doi: 10.17998/jlc.2016.16.1.63
Surgical resection is mainstay treatment of hepatocellular carcinoma (HCC). However, its prognosis is poor, because of the high incidence of HCC recurrence (cumulative 5-year HCC recurrence rate of 70-80%). The... -
- CITED
-
- Close
- SHARE
-
- Close
- Complete Response of Single Nodular Large Hepatocellular Carcinoma with Pulmonary Metastasis by Sequential Transarterial Chemoembolization and Sorafenib: A Case Report
-
Kim GH, Yu HM, Lim CJ, Cho SB
- KMID: 2198523
- J Liver Cancer.
- 2016 Mar;16(1):47-51.
- doi: 10.17998/jlc.2016.16.1.47
Current guidelines recommend sorafenib as the first-line molecular target agent for advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis and unresectable HCC. Sorafenib was reported to show survival benefit for patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Long Term Survival in Patient with Hepatocellular Carcinoma after Surgical Resection of Brain Metastasis: A Case Report
-
Lee JH, Yu HM, Cho SB
- KMID: 2198521
- J Liver Cancer.
- 2016 Mar;16(1):38-41.
- doi: 10.17998/jlc.2016.16.1.38
Brain metastasis is a rare condition of extraheptaic metastases in hepatocellular carcinoma (HCC). Patients with hepatocellular carcinoma and brain metastasis have rapidly worsened neurologic signs and symptoms, therefore it is... -
- CITED
-
- Close
- SHARE
-
- Close
- Experience and Expectation for Molecular Target Therapy in Hepatocellular Carcinoma
-
Kim DY
- KMID: 2198517
- J Liver Cancer.
- 2016 Mar;16(1):12-16.
- doi: 10.17998/jlc.2016.16.1.12
Sorafenib, the first-approved molecular targeted agent (MTA), is actively used in patients with advanced hepatocellular carcinoma (HCC) worldwide. Accumulating experiences suggest that the efficacy of this drug is modest and... -
- CITED
-
- Close
- SHARE
-
- Close
- Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
-
Kim DH, Min GH, Lee DW, Ahn KR, Kim JH, Suh SJ, Jung YK, Yim HJ
- KMID: 2198525
- J Liver Cancer.
- 2016 Mar;16(1):57-62.
- doi: 10.17998/jlc.2016.16.1.57
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Complete Response by Multidisciplinary Management in a Patient with Solitary Bone Metastasis after Curative Resection of Hepatocellular Carcinoma
-
Hwang S, Yang H, Lee HL, Jang JW, Bae SH, Choi JY, Yoon SK
- KMID: 2198524
- J Liver Cancer.
- 2016 Mar;16(1):52-56.
- doi: 10.17998/jlc.2016.16.1.52
Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with extrahepatic metastasis from HCC still remains dismal. The current study presents a case of HCC... -
- CITED
-
- Close
- SHARE
-
- Close
- Confirmation of HIF-1α Independent Pathway in the Progression of HepG2 Cells by Hypoxic Condition
-
Lee SW, Chong JU, Min SO, Kim KS
- KMID: 2198520
- J Liver Cancer.
- 2016 Mar;16(1):31-37.
- doi: 10.17998/jlc.2016.16.1.31
BACKGROUND/AIMS: When hepatocellular carcinoma (HCC) is exposed to hypoxic condition, HIF-1α is activated and results in angiogenesis and increased tumor burden. Although inhibition of HIF-1α may reduce tumor growth, there... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Rapid Progressive Extrahepatic Metastasis of Hepatocellular Carcinoma after Surgical Resection for Huge Single Mass
-
Jang ES, Kim H, Choi YR, Cho JY, Yoon YS, Han HS, Kim JH, Kim JW, Jeong SH
- KMID: 2198522
- J Liver Cancer.
- 2016 Mar;16(1):42-46.
- doi: 10.17998/jlc.2016.16.1.42
Hepatocellular carcinoma (HCC) shows a poor prognosis with high recurrence rate even after surgical resection. To improve prognosis of HCC patient, regular surveillance for high-risk group is recommended, but cost-benefit... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib
-
Kim JH, Yu HM, Hwang Y, Ko SY, Choe WH, Kwon SY
- KMID: 2198519
- J Liver Cancer.
- 2016 Mar;16(1):23-30.
- doi: 10.17998/jlc.2016.16.1.23
BACKGROUND/AIMS: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has been shown to improve survival of advanced HCC... -
- CITED
-
- Close
- SHARE
-
- Close
